A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of
GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor
activity against a variety of cell lines and models from different tumor origins.